Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-α and HSVtk: Perspectives for the generation of cancer vaccines

Gene Therapy

Volumn 4, Issue 11, 1997, Pages 1246-1255

  Santodonato, L ^a   D'Agostino, G ^a   Santini, S M ^a   Carlei, D ^a   Musiani, P ^b   Modesti, A ^b   Signorelli, P ^b   Belardelli, F ^a   Ferrantini, M ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cancer gene therapy; HSVtk; IFN

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; MONOCLONAL ANTIBODY;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER THERAPY; ERYTHROLEUKEMIA CELL; GENE THERAPY; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REJECTION; VISCERA;

ANIMALIA;

EID: 0030817757     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300518     Document Type: Article

References (38)

1. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent antitumor activity in vivo. Cell 1989; 57: 503-512.
2. Hussein AM. The potential applications of gene transfer in the treatment of patients with cancer: a concise review. Cancer Invest 1996; 14: 343-352.
3. Ferrantini M et al. αl-Interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in imnrunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res 1993; 53: 1107-1112.
4. + T cell-mediated rumor rejection and development of antitumor immunity. Comparative studies with IFN-γ-producing TS/A cells. J Immunol 1994; 153: 4604-4615.
5. Kaido T et al. IFN-αl gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int J Cancer 1995; 60: 1-9.
6. Gabriele L et al. Local and systemic response of mice to interferon-α-1-transfected Friend leukemia cells. Am J Pathol 1995; 147: 445-460.
7. Santodonato L et al. Cure of mice with established metastatic Friend leukemia cell tumors by a combined therapy with tumor cells expressing both mterferon-αl and herpes simplex thymsidine kinase followed by ganciclovir. Hum Gene Ther 1996; 7: 1-10.
8. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
9. Moolten F. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
10. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
11. Golumbek PT et al. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother 1992; 12: 224-230.
12. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993; 53: 3860-3864.
13. Caruso M et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024-7028.
14. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
15. Ram Z et al. In situ retrovirus-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53: 83-88.
16. Barba D, Hardin J, Ray J, Gage FH. Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg 1993; 79: 729-735.
17. Borrelli E, Heyman R, Hsi M, Evans RM. Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci USA 1988; 85: 7572-7576.
18. Ezzedine ZD et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biologist 1991; 3: 608-614.
19. Li Bi W, Parysek LM, Warnick R, Stambrook PJ. In vivo evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
20. Colombo BM et al. The "bystander effect': association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995; 6: 763-772.
21. Ram Z et al In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J Neurosurg 1994; 80: 535-540.
22. Chen S-H et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-3057.
23. Vile RG et al. Systemic gene therapy of inurine melanoma using tissue specific expression of the HSVfk gene involves an immune component. Cancer Res 1994; 54: 6228-6234.
24. Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wildtype tumor. Cancer Res 1994; 54: 1503-1506.
25. Barba D, Hardin J, Sadelain M, Gage FH. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 4348-4352.
26. Chen S-H et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92: 2577-2581.
27. O'Malley BW Jr et al. Combination gene therapy for oral cancer in a muriiie model. Cancer Res 1996; 56: 1737-1741.
28. Chen S-H et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996; 56: 37583762.
29. Belardelli F et al. Biologic and biochemical differences between in vitro and in vivo passaged Friend erythroleukemia cells. I. Tumorigenicity and capacity to metastasize. Int J Cancer 1984; 30: 389-395.
30. Nanni P et al. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metas 1983; 1: 373-380.
31. Belardelli F et al. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells, III. Inhibition of growth and necrosis of tumor implanted subcutaneously. Int J Cancer 1983; 31: 649-653.
32. Allione A et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, 1L-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54: 6022-6026.
33. Freeman SM et al. The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study. Hum Gene Ther 1995; 6: 927-939.
34. Freeman SM et al. The role of cytokines in mediating the bystander effect using HSVtk xenogenic cells. Cancer Left 1995; 92: 167-174.
35. Belardelli F, Grosser I. The neglected role of type I interferon in the T cell response: implications for its clinical use. Immunol Today 1996; 8: 369-372.
36. Affabris E, Jemma C, Rossi GB. Isolation of interferon-resistant variants of Friend erythroleukemia cells: effects of interferon and ouabain. Virology 1982; 120: 441-152.
37. Belardelli F et al. Studies on the expression of spontaneous and induced interferons in mouse peritoneal macrophages by means of monoclonal antibodies to mouse interferons. J Gen Virol 1987; 68: 2203-2212.
38. Ciolli V et al Combined IL-1 /IL-2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases. J Exp Med 1991; 173: 313-322.